Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016
Open Access
- 28 November 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (11) , e0206100
Abstract
Stimulants are considered the first-line treatment for Attention Deficit Hyperactivity Disorder (ADHD) in the US and they are used in other indications. Stimulants are also diverted for non-medical purposes. Ethnic and regional differences in ADHD diagnosis and in stimulant use have been identified in earlier research. The objectives of this report were to examine the pharmacoepidemiological pattern of these controlled substances over the past decade and to conduct a regional analysis. Data (drug weights) reported to the US Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System for four stimulants (amphetamine, methylphenidate, lisdexamfetamine, and methamphetamine) were obtained from 2006 to 2016 for Unites States/Territories. Correlations between state level use (mg/person) and Hispanic population were completed. Amphetamine use increased 2.5 fold from 2006 to 2016 (7.9 to 20.0 tons). Methylphenidate use, at 16.5 tons in 2006, peaked in 2012 (19.4 tons) and subsequently showed a modest decline (18.6 tons in 2016). The consumption per municipality significantly increased 7.6% for amphetamine and 5.5% for lisdexamfetamine but decreased 2.7% for methylphenidate (all p < .0005) from 2015 to 2016. Pronounced regional differences were also observed. Lisdexamfetamine use in 2016 was over thirty-fold higher in the Southern US (43.8 mg/person) versus the Territories (1.4 mg/person). Amphetamine use was about one-third lower in the West (48.1 mg/person) relative to the Northeastern (75.4 mg/person, p < .05) or the Midwestern (69.9 mg/person, p ≤ .005) states. States with larger Hispanic populations had significantly lower methylphenidate (r(49) = -0.63), lisdexamfetamine (B, r(49) = -0.49), and amphetamine (r(49) = -0.43) use. Total stimulant usage doubled in the last decade. There were dynamic changes but also regional disparities in the use of stimulant medications. Future research is needed to better understand the reasons for the sizable regional and ethnic variations in use of these controlled substances.Keywords
Funding Information
- National Institute of Environmental Health Sciences (T32 ES007060-31A1)
- Husson University School of Pharmacy (2013-01)
- Fahs-Beck Fund for Research and Experimentation (2017-01)
This publication has 80 references indexed in Scilit:
- State-Based and Demographic Variation in Parent-Reported Medication Rates for Attention-Deficit/Hyperactivity Disorder, 2007–2008Preventing Chronic Disease, 2013
- Stigma in attention deficit hyperactivity disorderADHD Attention Deficit and Hyperactivity Disorders, 2012
- A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem PersistsPLOS Medicine, 2012
- Executive Function Profile in the Offspring of Women That Smoked During PregnancyNicotine & Tobacco Research, 2011
- Academy of Pediatric Education and Leadership: Preparing Leaders for Educational InnovationPediatrics, 2011
- Abnormalities in parentally rated executive function in methamphetamine/polysubstance exposed childrenPharmacology Biochemistry and Behavior, 2011
- School accountability laws and the consumption of psychostimulantsJournal of Health Economics, 2011
- The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994–2003—A global pharmaceutical data analysisHealth Policy, 2010
- Longitudinal Mental Health Service and Medication Use for ADHD Among Puerto Rican Youth in Two ContextsJournal of the American Academy of Child & Adolescent Psychiatry, 2008
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005